AstraZeneca plans Shanghai cell therapy and innovation hub

AstraZeneca will build a cell therapy base and innovation centre in Shanghai. The site will produce CAR-T treatments for China and other broader Asian markets.

Xurve View
洞察:

AstraZeneca PLC has announced plans to establish a cell therapy manufacturing and supply base alongside a new innovation center in Shanghai. This development positions the United Kingdom-based pharmaceutical giant as the first global drugmaker to develop end-to-end cell therapy capabilities within China. The facility will focus on the production and supply of CAR-T cell therapies, which modify a patient's immune cells to target and destroy cancer cells, serving both the local market and other regions across Asia.

An AstraZeneca sign captured at the third China International Import Expo in Shanghai on November 6, 2020. REUTERS/Aly Song/File Photo